{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:22:58Z","timestamp":1776176578410,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1130,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:p>Deferasirox, a newly developed iron chelator, was coadministered orally with either a known inducer of drug metabolism or with cosubstrates for cytochrome P450 (CYP) to characterize the potential for drug\u2010drug interactions. In the induction assessment, single\u2010dose deferasirox pharmacokinetics were obtained in the presence and absence of a repeated\u2010dose regimen of rifampin. In the CYP3A interaction evaluation, midazolam and its active hydroxylated metabolite were assessed after single doses of midazolam in the presence and absence of steady\u2010state concentrations of deferasirox. To test for interaction at the level of CPY2C8, single\u2010dose repaglinide pharmacokinetics\/pharmacodynamics were determined with and without repeated\u2010dose administration of deferasirox. After rifampin, a significant reduction (44%) in plasma exposure (AUC) to deferasirox was observed. Upon coadministration of midazolam, there was a modest reduction of up to 22% in midazolam exposure (AUC, C<jats:sub>max<\/jats:sub>), suggesting a modest induction of CYP3A4\/5 by deferasirox. Deferasirox caused increases in repaglinide plasma C<jats:sub>max<\/jats:sub> and AUC of 1.5\u2010fold to over 2\u2010fold, respectively, with little change in blood glucose measures. Specific patient prescribing recommendations were established when coadministering deferasirox with midazolam, repaglinide, and rifampin. These recommendations may also apply to other substrates of CYP3A4\/5 and CYP2C8 or potent inducers of glucuronidation.<\/jats:p>","DOI":"10.1177\/0091270009340418","type":"journal-article","created":{"date-parts":[[2009,11,26]],"date-time":"2009-11-26T05:08:32Z","timestamp":1259212112000},"page":"205-213","source":"Crossref","is-referenced-by-count":33,"title":["Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once\u2010Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers"],"prefix":"10.1002","volume":"50","author":[{"given":"Andrej","family":"Skerjanec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jixian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Maren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rojkjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867033457610"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767150-00007"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21100"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13309-0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.13.2391"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109306"},{"key":"e_1_2_5_8_2","first-page":"1799","article-title":"Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis","volume":"20","author":"Shashaty G","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.006429"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008320316"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1345.021"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161110-00008"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70009-3"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001112"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0539-1"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050223"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111183"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007313327"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004263948"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0093-8"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.002"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1426"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009340418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009340418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:52:10Z","timestamp":1698954730000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009340418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1177\/0091270009340418"],"URL":"https:\/\/doi.org\/10.1177\/0091270009340418","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}